Evidence map›Paper›PMID 38564577›Full record

ArticlePloS one2024

RIO-kinase 2 is essential for hematopoiesis.

Jan-Erik Messling, Isabel Peña-Rømer, Ann Sophie Moroni, Sarah Bruestl, Kristian Helin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jan-Erik MesslingBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Isabel Peña-RømerThe Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-2987-6538
Ann Sophie MoroniBiotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-1910-4355
Sarah BruestlThe Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-3045-2855
Kristian HelinThe Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-1975-6097
Institute of Cancer Research · GBUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulation of protein synthesis is a key factor in hematopoietic stem cell maintenance and differentiation. Rio-kinase 2 (RIOK2) is a ribosome biogenesis factor that has recently been described an important regulator of human blood cell development. Additionally, we have previously identified RIOK2 as a regulator of protein synthesis and a potential target for the treatment of acute myeloid leukemia (AML). However, its functional relevance in several organ systems, including normal hematopoiesis, is not well understood. Here, we investigate the consequences of RIOK2 loss on normal hematopoiesis using two different conditional knockout mouse models. Using competitive and non-competitive bone marrow transplantations, we demonstrate that RIOK2 is essential for the differentiation of hematopoietic stem and progenitor cells (HSPCs) as well as for the maintenance of fully differentiated blood cells in vivo as well as in vitro. Loss of RIOK2 leads to rapid death in full-body knockout mice as well as mice with RIOK2 loss specific to the hematopoietic system. Taken together, our results indicate that regulation of protein synthesis and ribosome biogenesis by RIOK2 is essential for the function of the hematopoietic system.

Indexed as

Hematopoietic Stem CellsLeukemia, Myeloid, AcuteAnimalsBone Marrow TransplantationCell DifferentiationHematopoiesisHumansMiceMice, KnockoutProtein Serine-Threonine KinasesProtein Serine-Threonine KinasesRio-kinase 2, mouse

Identifiers

PMID38564577
PMCPMC10986946
OpenAlexW4393407768

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.